Attached files
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
Date of
report (Date of earliest event reported)
|
March 31,
2017
|
MEDITE CANCER DIAGNOSTICS, INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
|
333-143570
|
36-4296006
|
|
(Commission File
Number)
|
(IRS
Employer Identification No.)
|
|
4203 SW 34th St.
|
|
|
Orlando, FL
|
32811
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
(407)
996-9630
(Registrant’s
telephone number, including area code)
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2.
below):
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 1.01 Entry into a Material
Definitive Agreement
On
March 31, 2017, MEDITE Cancer Diagnostics, Inc., a Delaware
corporation (the "Company") entered into a Settlement Agreement of
Accrued Wages (the “Agreement”) with three (3) separate
employees. Under the terms of the Agreement, the Company agreed to
make total cash payments of $136,693, $97,840 and $95,612,
respectively, to the employees in three (3) installments over a
period of sixty (60) days from the date of the Agreement. In
addition, the Company further agreed to issue 406,754, 328,396 and
294,584 warrants for the common stock of the Company, respectively,
to the employees. The warrants are exercisable at $0.50 per share
for a period of five (5) years. Commencing on April 7, 2017, each
employee’s salary shall be increased to $90,000 per year. The
effective date of the Agreement is retroactive to December 31,
2016.
Item 9.01 Financial
Statements and Exhibits.
Exhibits
10.1.
Settlement Agreement for Accrued Wages with
Richard Domanik
10.2
Settlement Agreement for Accrued Wages with Daniel
Kusswurm
10.3
Settlement Agreement for Accrued Wages with Michael
Jolley
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
MEDITE
CANCER DIAGNOSTICS, INC.
|
|
|
|
|
|
|
|
|
|
|
Date:
April 4, 2017
|
By:
|
/s/ David E. Patterson
|
|
|
|
David
E. Patterson
|
|
|
|
Chief
Executive Officer
|
|
|